Allogene Therapeutics, Inc.
ALLO Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.23
KIRA · Stoqly’s AI analyst, in plain words
- Allogene Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Allogene Therapeutics, Inc. lost $191M in fiscal 2025.
- Free cash flow was −$150M in fiscal 2025, — of revenue.
Market cap
$405M
P/E
—
Revenue
$0.0M
Net income
−$191M
Free cash flow
−$150M
Operating margin
—
Allogene Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$191M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Allogene Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Allogene Therapeutics, Inc.
- CIK
- 0001737287
Allogene Therapeutics, Inc. · ALLO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $114M | $0.2M | $0.1M | $0.0M | $0.0M |
| Revenue growth | — | −99.9% | −39.1% | −76.8% | −100.0% |
| Operating margin | −157.9% | −215,087.2% | −344,986.3% | −1,241,813.6% | — |
| Net income | −$182M | −$340M | −$327M | −$258M | −$191M |
| Net margin | −159.6% | −218,214.1% | −344,489.5% | −1,170,863.6% | — |
| Diluted EPS | −$1.34 | −$2.38 | −$2.09 | −$1.32 | −$0.87 |
| Cash | |||||
| Cash from operations | −$185M | −$221M | −$238M | −$200M | −$149M |
| Capital expenditure | $21.4M | $5.2M | $1.5M | $0.7M | $0.4M |
| Free cash flow | −$206M | −$226M | −$239M | −$201M | −$150M |
| FCF margin | −180.8% | −144,685.9% | −251,841.1% | −913,609.1% | — |
| Share count change | 12.8% | 5.4% | 9.6% | 24.1% | 13.2% |
| Debt and strength | |||||
| Cash and short-term investments | $457M | $517M | $449M | $292M | $250M |
| Shareholders' equity | $925M | $667M | $512M | $422M | $293M |
| Current ratio | 9.8x | 9.8x | 12.4x | 8.5x | 7.9x |
| Interest coverage | — | — | — | −1,509.4x | −194.7x |
| Returns and quality | |||||
| Return on equity | −18.8% | −42.8% | −55.5% | −55.1% | −53.4% |
| Return on tangible equity | −19.7% | −51.0% | −63.9% | −61.0% | −65.3% |
| Piotroski F-score | 3 | 2 | 2 | 2 | 2 |
| Altman Z'' | 6.4 | 0.7 | −2.9 | −7.5 | −13.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.7M
6 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Allogene Therapeutics, Inc. · ALLO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.23 a share, the company is worth $405M.
Source: SEC EDGAR XBRL filings (CIK 0001737287). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.